Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Acute Ischaemic Stroke
NCT03639922Phase 3Unknown
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Imatinib with Placebo (2 arms). Primary endpoint: Functional independency at 3 months as measured by modified Rankin Scale (mRS) Score 0-2. Status: unknown.
02
Drugs
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03639922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639922.